argenx SE (NASDAQ:ARGX) Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,861 shares of the company's stock after purchasing an additional 3,493 shares during the quarter. Russell Investments Group Ltd. owned about 0.05% of argenx worth $11,360,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Marks Group Wealth Management Inc increased its position in argenx by 42.6% during the fourth quarter. Marks Group Wealth Management Inc now owns 1,034 shares of the company's stock valued at $393,000 after acquiring an additional 309 shares during the last quarter. New York State Common Retirement Fund increased its position in argenx by 15.0% during the fourth quarter. New York State Common Retirement Fund now owns 146,168 shares of the company's stock valued at $55,607,000 after acquiring an additional 19,032 shares during the last quarter. abrdn plc bought a new position in argenx during the fourth quarter valued at $27,952,000. Federated Hermes Inc. increased its position in argenx by 7.4% during the fourth quarter. Federated Hermes Inc. now owns 356,507 shares of the company's stock valued at $135,626,000 after acquiring an additional 24,416 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its position in argenx by 2.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,530 shares of the company's stock valued at $582,000 after acquiring an additional 41 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

Wall Street Analyst Weigh In

ARGX has been the topic of a number of analyst reports. HC Wainwright reiterated a "buy" rating and set a $451.00 price objective on shares of argenx in a research report on Thursday, April 18th. Wells Fargo & Company upped their price target on shares of argenx from $472.00 to $478.00 and gave the stock an "overweight" rating in a report on Tuesday, February 20th. Robert W. Baird cut their price target on shares of argenx from $505.00 to $490.00 and set an "outperform" rating on the stock in a report on Friday, March 1st. Truist Financial upped their price target on shares of argenx from $370.00 to $440.00 and gave the stock a "buy" rating in a report on Tuesday, March 5th. Finally, Piper Sandler upped their price target on shares of argenx from $518.00 to $522.00 and gave the stock an "overweight" rating in a report on Friday, January 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $528.16.

argenx Price Performance

Shares of ARGX stock traded up $5.58 during mid-day trading on Monday, hitting $393.78. 203,738 shares of the stock traded hands, compared to its average volume of 309,215. The stock has a market cap of $23.40 billion, a P/E ratio of -76.61 and a beta of 0.67. The stock's fifty day moving average is $383.45 and its two-hundred day moving average is $411.22. argenx SE has a 52-week low of $327.73 and a 52-week high of $550.76.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The firm had revenue of $417.84 million for the quarter, compared to analysts' expectations of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same period in the previous year, the company posted ($0.70) earnings per share. As a group, equities analysts forecast that argenx SE will post -2.09 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.